Angiogenesis and prostate cancer: MicroRNAs comes into view.

[1]  Michael R Hamblin,et al.  Role of non-coding RNAs in neuroblastoma , 2023, Cancer Gene Therapy.

[2]  Michael R Hamblin,et al.  Non-coding RNAs and Exosomal Non-coding RNAs in Traumatic Brain Injury: the Small Player with Big Actions , 2023, Molecular Neurobiology.

[3]  Wenwei Li,et al.  Circ_0005276 Promotes Prostate Cancer Progression Through the Crosstalk of miR-128-3p/DEPDC1B Axis. , 2023, Biochemical genetics.

[4]  Yang Xiang,et al.  Hsa_circ_0001165 Regulates the Malignant Phenotype and Angiogenesis of Prostate Cancer Cells through miR-654-3p/DDAH1 , 2023, Biotechnology and Bioprocess Engineering.

[5]  Ling Zhang,et al.  Circ_0057558 accelerates the development of prostate cancer through miR-1238-3p/SEPT2 axis. , 2023, Pathology, research and practice.

[6]  Michael R Hamblin,et al.  Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression , 2022, Frontiers in Cell and Developmental Biology.

[7]  S. Sadeghi,et al.  Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis , 2022, Frontiers in Oncology.

[8]  A. Jalil,et al.  MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells’ Capability to Proliferate and Migrate , 2022, Drug Research.

[9]  W. Song,et al.  Tumor-derived miR-130b-3p induces cancer-associated fibroblast activation by targeting SPIN90 in luminal A breast cancer , 2022, Oncogenesis.

[10]  Arash Salmaninejad,et al.  Virus, Exosome, and MicroRNA: New Insights into Autophagy. , 2022, Advances in experimental medicine and biology.

[11]  X. Zeng,et al.  Research progress on the circRNA/lncRNA-miRNA-mRNA axis in gastric cancer. , 2022, Pathology, research and practice.

[12]  Michael R Hamblin,et al.  Cytokines and microRNAs in SARS-CoV-2: What do we know? , 2022, Molecular Therapy - Nucleic Acids.

[13]  A. Khatami,et al.  The expression patterns of MALAT-1, NEAT-1, THRIL, and miR-155-5p in the acute to the post-acute phase of COVID-19 disease , 2022, The Brazilian Journal of Infectious Diseases.

[14]  Michael R Hamblin,et al.  MicroRNA let-7 and viral infections: focus on mechanisms of action , 2022, Cellular & molecular biology letters.

[15]  S. Zappavigna,et al.  MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer , 2022, Journal of experimental & clinical cancer research : CR.

[16]  P. Mabeta,et al.  LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities , 2022, Genes.

[17]  Yanan Lu,et al.  Circular RNA circ_0062019 exerts oncogenic properties in prostate cancer via mediating miR‐1253/NRBP1 axis , 2021, Andrologia.

[18]  L. Jia,et al.  miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways , 2021, Experimental and Therapeutic Medicine.

[19]  I. Park,et al.  miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor , 2021, AntiCancer Research.

[20]  Michael R Hamblin,et al.  Roles of Non-coding RNAs and Angiogenesis in Glioblastoma , 2021, Frontiers in Cell and Developmental Biology.

[21]  Michael R Hamblin,et al.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer , 2021, Molecular therapy oncolytics.

[22]  Michael R Hamblin,et al.  Non-coding RNAs related to angiogenesis in gynecological cancer. , 2021, Gynecologic oncology.

[23]  Michael R Hamblin,et al.  Cell death pathways and viruses: Role of microRNAs , 2021, Molecular therapy. Nucleic acids.

[24]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[25]  Taowei Yang,et al.  Circular RNA CircNOLC1, Upregulated by NF-KappaB, Promotes the Progression of Prostate Cancer via miR-647/PAQR4 Axis , 2021, Frontiers in Cell and Developmental Biology.

[26]  M. Rubin,et al.  Prostate cancer hijacks the microenvironment , 2021, Nature Cell Biology.

[27]  Yue-Ming Li,et al.  Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers , 2020, Frontiers in Oncology.

[28]  M. Moghoofei,et al.  The role of HPV gene expression and selected cellular MiRNAs in lung cancer development. , 2020, Microbial pathogenesis.

[29]  Xin Wei,et al.  Long noncoding RNA LINC00261 suppresses prostate cancer tumorigenesis through upregulation of GATA6-mediated DKK3 , 2020, Cancer cell international.

[30]  Arash Salmaninejad,et al.  Exosomal microRNAs: novel players in cervical cancer. , 2020, Epigenomics.

[31]  Michael R Hamblin,et al.  Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. , 2020, Pathology, research and practice.

[32]  M. Moghoofei,et al.  The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. , 2020, International immunopharmacology.

[33]  Y. Tao,et al.  miRNA-based biomarkers, therapies, and resistance in Cancer , 2020, International journal of biological sciences.

[34]  Zhenwei Yang,et al.  miR-185 inhibits prostate cancer angiogenesis induced by the nodal/ALK4 pathway , 2020, BMC Urology.

[35]  Peng Wang,et al.  SP1‐mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR‐377 to facilitate prostate cancer progression through regulation of ZIC5 , 2020, Journal of cellular physiology.

[36]  B. Schilling,et al.  miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro , 2020, Journal of clinical medicine.

[37]  M. Moghoofei,et al.  The role of miR‐146a in viral infection , 2019, IUBMB life.

[38]  Gonghui Li,et al.  lncRNA UCA1 Functions as a ceRNA to Promote Prostate Cancer Progression via Sponging miR143 , 2019, Molecular therapy. Nucleic acids.

[39]  A. Vacca,et al.  Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs , 2019, Journal of clinical medicine.

[40]  Zhenming Jiang,et al.  Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1 , 2019, Gene Therapy.

[41]  A. Dimberg,et al.  Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.

[42]  Michael R Hamblin,et al.  Pathogenic role of exosomes and microRNAs in HPV‐mediated inflammation and cervical cancer: A review , 2019, International journal of cancer.

[43]  Q. Xie,et al.  MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis , 2019, Clinical and Translational Oncology.

[44]  Zhenming Jiang,et al.  Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial–mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2 , 2019, Cancer Cell International.

[45]  A. Dudley,et al.  Models and molecular mechanisms of blood vessel co-option by cancer cells , 2019, Angiogenesis.

[46]  Hamed Mirzaei,et al.  microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer , 2019, Journal of cellular physiology.

[47]  A. Poprach,et al.  MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients , 2019, Cancer Genomics & Proteomics.

[48]  F. Boccardo,et al.  Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer , 2019, Cancers.

[49]  Rajesh Singh,et al.  Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway , 2019, Cancers.

[50]  Junhong Han,et al.  miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1 , 2019, BMC cancer.

[51]  S. Oltean,et al.  Targeting Angiogenesis in Prostate Cancer , 2019, International journal of molecular sciences.

[52]  N. Calvo,et al.  PTHrP treatment of colon cancer cells promotes tumor associated-angiogenesis by the effect of VEGF , 2019, Molecular and Cellular Endocrinology.

[53]  Raghunath Chatterjee,et al.  Liquid biopsy: miRNA as a potential biomarker in oral cancer. , 2019, Cancer epidemiology.

[54]  Asghar Fallah,et al.  Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[55]  H. Keyvani,et al.  microRNAs: Key players in virus‐associated hepatocellular carcinoma , 2018, Journal of cellular physiology.

[56]  E. Ruíz-García,et al.  AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). , 2018, International journal of molecular medicine.

[57]  L. Qiang,et al.  Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer. , 2018, Molecular pharmaceutics.

[58]  O. Bălăcescu,et al.  MiRNA-Based Therapeutics in Oncology, Realities, and Challenges , 2018, Antisense Therapy.

[59]  P. Barata,et al.  Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer , 2018, Investigational New Drugs.

[60]  Hongwei Zhang,et al.  Reciprocal regulations between miRNAs and HIF-1α in human cancers , 2018, Cellular and Molecular Life Sciences.

[61]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[62]  Lihang Liu,et al.  EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer , 2018, Experimental cell research.

[63]  Mohammad Mashreghi,et al.  Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis , 2018, Journal of cellular physiology.

[64]  Hong Chen,et al.  miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1 , 2018, Oncology letters.

[65]  Jin-Tang Dong,et al.  The miR‐203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK‐3β/β‐CATENIN signal pathway , 2018, IUBMB life.

[66]  Li Yang,et al.  MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901. , 2018, Oncology reports.

[67]  N. Dumaz,et al.  The role of RICTOR downstream of receptor tyrosine kinase in cancers , 2018, Molecular Cancer.

[68]  Cheng Chen,et al.  New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications , 2018, Molecular Cancer.

[69]  G. Zeng,et al.  miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression , 2018, Oncology reports.

[70]  Zhiqiang Zhang,et al.  The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression , 2018, Oncotarget.

[71]  B. Jiang,et al.  Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer , 2017, Oncotarget.

[72]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[73]  B. Han,et al.  MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer , 2017, Cellular Physiology and Biochemistry.

[74]  Ning-Bo Hao,et al.  The role of miRNA and lncRNA in gastric cancer , 2017, Oncotarget.

[75]  F. Winkler.  Hostile takeover: how tumours hijack pre‐existing vascular environments to thrive , 2017, The Journal of pathology.

[76]  Yi Liu,et al.  Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis , 2017, International journal of oncology.

[77]  Shaker A. Mousa,et al.  The Role of Angiogenesis in Cancer Treatment , 2017, Biomedicines.

[78]  H. Zeng,et al.  Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α. , 2017, Oncotarget.

[79]  Antonio Arévalo,et al.  Exosomal and Non‐Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis , 2017, The Prostate.

[80]  H. Mirzaei,et al.  Green tea and its anti-angiogenesis effects. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[81]  Chin-Lee Wu,et al.  MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer , 2017, Molecular Cancer.

[82]  P. Pauwels,et al.  Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer , 2017, Clinical and Translational Oncology.

[83]  Peng Guo,et al.  Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer , 2016, Oncotarget.

[84]  Elena Aréchaga Ocampo,et al.  Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer , 2016, Scientific Reports.

[85]  A. Hamid,et al.  The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. , 2016, Acta medica Indonesiana.

[86]  Yong-jie Lu,et al.  MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity , 2016, Oncotarget.

[87]  S. Donnini,et al.  Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and −186 expression: Novel mechanism of VEGF modulation in prostate cancer , 2016, Oncotarget.

[88]  R. Gambari,et al.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review) , 2016, International journal of oncology.

[89]  M. Hendrix,et al.  Plasticity underlies tumor progression: role of Nodal signaling , 2016, Cancer and Metastasis Reviews.

[90]  Jiang-feng Xu,et al.  MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling , 2016, Tumor Biology.

[91]  L. A. Antón Aparicio,et al.  Role of taxanes in advanced prostate cancer , 2016, Clinical and Translational Oncology.

[92]  G. Yousef,et al.  miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  Wen-Juan Ni,et al.  Dynamic miRNA–mRNA paradigms: New faces of miRNAs , 2015, Biochemistry and biophysics reports.

[94]  Varsha Harish,et al.  MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence , 2015, Oncotarget.

[95]  Chuanhe Yang,et al.  The Role of miR‐21 in Cancer , 2015, Drug development research.

[96]  O. Mir,et al.  Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis , 2015, Investigational New Drugs.

[97]  H. Ying,et al.  Hypoxia-inducible miR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer , 2015, Scientific Reports.

[98]  B. Zetter,et al.  The Contribution of Angiogenesis to the Process of Metastasis. , 2015, Cancer journal.

[99]  R. Santi,et al.  mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity , 2015, Endocrine-related cancer.

[100]  Wei-De Zhong,et al.  miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer , 2015, Clinical Cancer Research.

[101]  L. Pereira de Almeida,et al.  MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[102]  Li Yang,et al.  Regulation of circRNA biogenesis , 2015, RNA biology.

[103]  J. Moul,et al.  A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy , 2015, Prostate Cancer and Prostatic Disease.

[104]  Jennifer A. Doudna,et al.  Dicer-TRBP complex formation ensures accurate mammalian microRNA biogenesis. , 2015, Molecular cell.

[105]  Hong Zhu,et al.  MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells , 2015, BMC Cancer.

[106]  Sung-Hoon Kim,et al.  Upregulation of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells , 2015, Journal of Cancer.

[107]  V. Baumann,et al.  miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. , 2014, Future medicinal chemistry.

[108]  Jianping Zhang,et al.  Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer , 2014, Cancer science.

[109]  E. Hirsch,et al.  PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.

[110]  Qin Chen,et al.  MiR‐130b suppresses prostate cancer metastasis through down‐regulation of MMP2 , 2014, Molecular carcinogenesis.

[111]  J. Pelling,et al.  Apigenin inhibits TGF‐β‐induced VEGF expression in human prostate carcinoma cells via a Smad2/3‐ and Src‐dependent mechanism , 2014, Molecular carcinogenesis.

[112]  G. Baldwin,et al.  The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer , 2014, Cancer medicine.

[113]  F. Saad,et al.  Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Bo Wang,et al.  Correction: MiR-130b Is a Prognostic Marker and Inhibits Cell Proliferation and Invasion in Pancreatic Cancer through Targeting STAT3 , 2013, PLoS ONE.

[115]  M. Binaschi,et al.  MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. , 2013, Neoplasia.

[116]  M. Cieśla,et al.  Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. , 2013, Antioxidants & redox signaling.

[117]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[118]  Randy S. Schrecengost,et al.  Molecular pathogenesis and progression of prostate cancer. , 2013, Seminars in oncology.

[119]  M. Carducci,et al.  A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). , 2013 .

[120]  A. Agarwal,et al.  Functional proteomic analysis of seminal plasma proteins in men with various semen parameters , 2013, Reproductive Biology and Endocrinology.

[121]  Cheng Huang,et al.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.

[122]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[123]  A. Llorente,et al.  Exosomal miRNAs as Biomarkers for Prostate Cancer , 2013, Front. Genet..

[124]  P. Leung,et al.  Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells , 2013, PloS one.

[125]  Sebastian D. Mackowiak,et al.  Circular RNAs are a large class of animal RNAs with regulatory potency , 2013, Nature.

[126]  J. Kjems,et al.  Natural RNA circles function as efficient microRNA sponges , 2013, Nature.

[127]  X. Wan,et al.  miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer , 2013, Medical Oncology.

[128]  Z. Yao,et al.  CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer , 2013, Oncogene.

[129]  Yoon-Jae Cho,et al.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward. , 2012, Cold Spring Harbor perspectives in medicine.

[130]  Lihua Zhang,et al.  MiR‐146a suppresses tumor growth and progression by targeting EGFR pathway and in a p‐ERK‐dependent manner in castration‐resistant prostate cancer , 2012, The Prostate.

[131]  H. Moses,et al.  Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk , 2012, Breast Cancer Research.

[132]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[133]  Charles Gawad,et al.  Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types , 2012, PloS one.

[134]  D. Ingber,et al.  Forty-Year Journey of Angiogenesis Translational Research , 2011, Science Translational Medicine.

[135]  Y. Matsumura,et al.  Exosome can prevent RNase from degrading microRNA in feces. , 2011, Journal of gastrointestinal oncology.

[136]  U. Huynh-Do,et al.  The Role of PTEN in Tumor Angiogenesis , 2011, Journal of oncology.

[137]  J. Inazawa,et al.  The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. , 2011, Cancer research.

[138]  Shafiq A. Khan,et al.  Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: Autocrine effects on cell proliferation and migration , 2011, The Prostate.

[139]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[140]  B. Jiang,et al.  MiR-21 Induced Angiogenesis through AKT and ERK Activation and HIF-1α Expression , 2011, PloS one.

[141]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[142]  G. Melillo,et al.  Inhibition of Hypoxia Inducible Factor-1α by Dihydroxyphenylethanol, a Product from Olive Oil, Blocks Microsomal Prostaglandin-E Synthase-1/Vascular Endothelial Growth Factor Expression and Reduces Tumor Angiogenesis , 2010, Clinical Cancer Research.

[143]  Guanghai Yang,et al.  MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.

[144]  S. Alahari,et al.  miRNA control of tumor cell invasion and metastasis , 2010, International journal of cancer.

[145]  Michael K. Wendt,et al.  Mechanisms of the epithelial-mesenchymal transition by TGF-beta. , 2009, Future oncology.

[146]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[147]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[148]  Sarah M Gressett,et al.  Intricacies of Bevacizumab-Induced Toxicities and Their Management , 2009, The Annals of pharmacotherapy.

[149]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[150]  Shalini Jain,et al.  Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. , 2008, Cancer research.

[151]  M. Coffey,et al.  Hypoxia in prostate cancer: a powerful shield against tumour destruction? , 2008, Cancer treatment reviews.

[152]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[153]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[154]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[155]  D. Bartel,et al.  Intronic microRNA precursors that bypass Drosha processing , 2007, Nature.

[156]  I. Eltoum,et al.  Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. , 2007, Cancer research.

[157]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[158]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[159]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[160]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[161]  B. Cullen,et al.  Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. , 2004, RNA.

[162]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[163]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[164]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[165]  R. Altman,et al.  Investigating hypoxic tumor physiology through gene expression patterns , 2003, Oncogene.

[166]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[167]  M. Goumans,et al.  Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.

[168]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[169]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  P. Kantoff,et al.  Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. , 2001, Cancer research.

[171]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[172]  J. D. Chapman,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.

[173]  D. Petrylak.  Docetaxel (Taxotere) in hormone-refractory prostate cancer. , 2000, Seminars in oncology.

[174]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[175]  C. Stein.  Mechanisms of action of taxanes in prostate cancer. , 1999, Seminars in oncology.

[176]  D. Bostwick,et al.  Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. , 1999, Urology.

[177]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[178]  D. Bostwick,et al.  Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.

[179]  G. Panayotou,et al.  Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.

[180]  V. Laudone,et al.  Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.

[181]  K. Griffiths,et al.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. , 1996, British Journal of Cancer.

[182]  E. Small,et al.  Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[184]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[185]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[186]  Michael R Hamblin,et al.  Exosomal MicroRNA Profiling. , 2023, Methods in molecular biology.

[187]  C. Sáez,et al.  Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer. , 2018, Methods in molecular biology.

[188]  S. Sahoo,et al.  Exosomes-Based Gene Therapy for MicroRNA Delivery. , 2017, Methods in molecular biology.

[189]  Baocun Sun,et al.  Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. , 2017, American journal of cancer research.

[190]  B. Xiong,et al.  MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. , 2013, International journal of oncology.

[191]  Wei Wu,et al.  MicroRNA-Based Therapeutics for Cancer , 2012, BioDrugs.

[192]  D. Reese,et al.  Treatment Options in Hormone-Refractory Prostate Cancer , 2012, Drugs.

[193]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[194]  G. Semenza,et al.  Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.

[195]  Lothar Schweigerer,et al.  Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy , 2004, Angiogenesis.